

# Accepted Manuscript



Clinical course and prognostic factors in conservatively managed carpal tunnel syndrome: A systematic review

Dr Claire L. Burton, MBChB, MMedSci, Dr Linda S. Chesterton, PhD, Dr Ying Chen, PhD, Dr Daniëlle AWM. van der Windt, PhD

PII: S0003-9993(15)01234-4

DOI: [10.1016/j.apmr.2015.09.013](https://doi.org/10.1016/j.apmr.2015.09.013)

Reference: YAPMR 56325

To appear in: *ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION*

Received Date: 6 July 2015

Revised Date: 17 September 2015

Accepted Date: 21 September 2015

Please cite this article as: Burton CL, Chesterton LS, Chen Y, van der Windt DA, Clinical course and prognostic factors in conservatively managed carpal tunnel syndrome: A systematic review, *ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION* (2015), doi: 10.1016/j.apmr.2015.09.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Running Head: The Course and Prognosis of Carpal Tunnel Syndrome**

2 **Title: Clinical course and prognostic factors in conservatively managed carpal**  
3 **tunnel syndrome: A systematic review**

4 Dr Claire L Burton, MBChB, MMedSci <sup>a</sup>

5 Dr Linda S Chesterton, PhD <sup>a</sup>

6 Dr Ying Chen, PhD <sup>a</sup>

7 Dr Daniëlle AWM van der Windt, PhD <sup>a</sup>

8 <sup>a</sup> Arthritis Research UK Primary Care Centre, Research Institute for Primary Care &  
9 Health Sciences, Keele University, Keele, Staffordshire. ST5 5BG. UK

10 C Burton is supported by National Institute for Health Research In Practice  
11 Fellowship (Reference Number NIHR-IPF-2013-07-002). The views expressed in this  
12 publication are those of the authors and not necessarily those of the NHS, the  
13 National Institute for Health Research or the Department of Health.

14 D van der Windt is a member of PROGRESS Medical Research Council Prognosis  
15 Research Strategy (PROGRESS) Partnership (G0902393/99558).

16 We do not have any conflicts of interest to declare.

17 Corresponding author – Dr Claire L Burton. [c.burton@keele.ac.uk](mailto:c.burton@keele.ac.uk) Arthritis Research  
18 UK Primary Care Centre, Research Institute for Primary Care & Health Sciences,  
19 Keele University, Keele, Staffordshire. ST5 5BG. UK. Tel +44 (0) 1782 733905 Fax  
20 +44 (0) 1782 734719

21

1 **Running Head: The Course and Prognosis of Carpal Tunnel Syndrome**

2 **Title: Clinical course and prognostic factors in conservatively managed carpal**  
3 **tunnel syndrome: A systematic review**

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

ACCEPTED MANUSCRIPT

**20 Abstract****21 Objective**

22 To summarize the available evidence regarding the course of symptoms and  
23 prognostic factors in patients diagnosed with CTS and treated conservatively. Details  
24 of the protocol for this systematic review were registered on PROSPERO  
25 (CRD42013006608).

**26 Data Sources & Study Selection**

27 Through a systematic search we identified 16 cohort studies from hospital and  
28 clinical database settings, describing the course of CTS.

**29 Data Extraction**

30 Methodological bias was assessed using the Quality in Prognosis Studies (QUIPS)  
31 tool. A high risk of bias, (predominantly relating to study attrition, confounding and/or  
32 statistical analysis and reporting) was judged to be present in 8 studies. Designs  
33 showed wide variability with respect to: characteristics of the included population;  
34 definition of CTS; assessment of prognostic factors; types of interventions provided  
35 and types of outcome measures applied. This prevented pooled estimates being  
36 produced.

**37 Data Synthesis**

38 Negative outcome at 3 years follow-up of conservatively treated participants ranged  
39 from 23 – 89%. Four included studies observed the rate of surgical intervention  
40 following initial conservative management and found this to be 57-66%. Evidence  
41 regarding factors predicting the negative outcome of no treatment or conservative

42 treatment was graded taking into account the number of studies evaluating the  
43 factor, the methodological quality of these studies and the consistency of the  
44 available evidence. There was 100% agreement in at least 3 or more cohorts with a  
45 medium or high risk of bias that: symptom duration; a positive Phalen's test; and  
46 thenar wasting were associated with a negative outcome of conservative  
47 management, however not all results were statistically significant and hence the  
48 overall judgement remained inconclusive.

#### 49 **Conclusions**

50 Results of this review should be treated with caution due to the heterogeneity of  
51 studies, and the risks of bias identified. However, the course of CTS appears  
52 variable and poor prognosis may be predicted by a longer symptom duration, a  
53 positive Phalen's test and thenar wasting.

54 **Key words:** carpal tunnel syndrome; disease management; prognosis

55

#### 56 **Abbreviations**

57	CTS	carpal tunnel syndrome
58	NSAIDS	non-steroidal anti-inflammatory drugs
59	PF	prognostic factor
60	QUIPS	Quality in Prognostic Studies

61

62

63

64 **Introduction**

65 Carpal tunnel syndrome (CTS) is a chronic focal compressive neuropathy caused by  
66 the entrapment of the median nerve at the level of the carpal tunnel <sup>1</sup>. CTS is the  
67 most common of the entrapment neuropathies, accounting for 90% of presentations  
68 <sup>2</sup> and is characterised by numbness, tingling, hand and arm pain and muscle  
69 dysfunction <sup>3</sup>. Between 55–65% of CTS cases present bilaterally<sup>4</sup> and the  
70 condition can be associated with hypothyroidism, diabetes, and rheumatoid  
71 arthritis, amongst others. CTS may present in late pregnancy but is usually transient.

72 Studies in different countries have reported varying results with respect to the  
73 incidence of CTS <sup>5</sup>. A survey of the Skåne Health Care Register in Sweden by  
74 Atroshi et al was age-adjusted to the 2000 US standard population to allow  
75 comparison with the results of a US based survey of the Rochester Epidemiology  
76 Project <sup>6</sup>. The estimated incidence of CTS in Sweden was reported as 324 per  
77 100,000 in women compared with 542 in the US, and in men, 166 in Sweden  
78 compared with 303 in the US <sup>5,6</sup>. The explanation for variation between countries is  
79 unknown, however suggested possibilities include: differences in healthcare seeking  
80 behaviour and variation in aetiological factors including occupation, diabetes and  
81 inflammatory joint disease <sup>5</sup>.

82 The treatment of CTS is often categorised as either surgical or conservative (non-  
83 surgical). Surgical treatment is generally recommended for those with severe CTS  
84 i.e. evidence of denervation of the median nerve, whilst conservative treatments are  
85 recommended for the initial management of those who have intermittent or mild  
86 symptoms or in whom surgery is contraindicated <sup>7</sup>. The US-standardised annual

87 incidence of carpal tunnel release surgery per 100,000 persons was 166 in Sweden  
88 compared with 171 in the US and, among men, 58 in Sweden compared with 96 in  
89 the US<sup>5,6</sup>. Examples of conservative treatment include; oral steroids, steroid  
90 injections, physical therapy, electrotherapy, night splinting and workplace  
91 alterations<sup>8</sup>. In UK primary care, steroid injections and night splinting form the  
92 mainstay of conservative treatment options, as indicated by national care pathways  
93 (for example National Institute for Health and Care Excellence Clinical Knowledge  
94 Summaries)<sup>9,10</sup>. Guidelines for the management of CTS by the American  
95 Association of Orthopaedic Surgeons<sup>11</sup> conclude that patients with more severe and  
96 prolonged CTS may not benefit from extended conservative treatment. However the  
97 authors were unable to recommend in which patients conservative treatments were  
98 unlikely to be effective<sup>11</sup>.

99 Cochrane systematic reviews of conservative treatments for CTS<sup>12</sup> have included  
100 the assessment of local corticosteroid injections<sup>13</sup> and splinting<sup>7</sup>. In respect of  
101 splinting, the authors conclude that there is limited evidence that night splinting is  
102 more effective than no treatment in the short term. They do however suggest that  
103 that more research is needed on the long-term effects of this intervention<sup>7</sup>. With  
104 regard to steroid injections, it was concluded that robust evidence demonstrates  
105 clinical improvement up to one month compared to placebo but relief beyond this  
106 time period has not yet been shown<sup>13</sup>.

107 With on-going clinical uncertainty regarding the most effective management strategy  
108 for CTS, there is a clear need for a greater understanding of the likely long term  
109 course of CTS symptoms (overall prognosis) of the condition and patient factors that  
110 may be associated with outcome (prognostic factors).

111 Outcomes and predictors of surgical outcome have been well reported in the  
112 literature, however few studies and no systematic reviews have been performed to  
113 summarise the evidence for prognosis and prognostic factors in conservatively  
114 managed disease, i.e. that which can be delivered in a primary care environment. An  
115 estimate of average prognosis is required by public health policy makers in order for  
116 the population burden of a condition to be assessed. Understanding the future  
117 outcomes of patients with a particular condition in relation to current practice and  
118 even in the absence of clinical care (the natural history) is crucial as it allows the  
119 potential impact of interventions to be more fully assessed<sup>14</sup>. Such information is not  
120 only important when considering the potential benefits of interventions, but also in  
121 order to inform patients, clinicians and policy makers of the potential harms,  
122 variations (such as underuse, overuse, misuse) and potential impact on healthcare  
123 efficiencies<sup>14</sup>.

124 This systematic review and narrative synthesis initially focuses on summarising the  
125 prognosis research regarding the general course of CTS. The 'startpoint' of this  
126 review will be the point of diagnosis of CTS that is being treated conservatively or  
127 with no clinical treatment. The 'endpoint' will vary depending upon on the primary  
128 study. This synthesis therefore seeks to describe the course of CTS, being managed  
129 with either no intervention or with conservative approaches.

130 The second part of this systematic review aims to identify predictors of long-term  
131 outcome (prognostic factors) in CTS. A prognostic factor (PF) is *"any measure that,*  
132 *among people with a given health condition (startpoint), is associated with a*  
133 *subsequent clinical outcome (endpoint)*<sup>15</sup>. Prognostic factor research thus seeks to  
134 identify the predictive value of such factors.



135 Research of prognostic factors aims to identify features that could potentially  
136 contribute to the development of prognostic models or represent predictors of  
137 differential treatment response, which may further contribute to a stratified care  
138 approach to a condition. Prognostic factors may also represent modifiable targets for  
139 interventions and could hence lead to the development of new management  
140 strategies through an improved understanding of disease mechanisms<sup>15</sup>.

## 141 **Methods**

### 142 ***2.1 Identification and selection of the literature***

143 Details of the protocol for this systematic review were registered on PROSPERO  
144 (CRD42013006608) and can be accessed at  
145 [http://www.crd.york.ac.uk/PROSPERO/display\\_record.asp?ID=CRD42013006608#](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013006608#).  
146 VYk\_RfIVhBc. Eligible publications had to report; the course of CTS symptoms  
147 (persistence / recovery or severity of pain or other symptoms), and / or the  
148 association between a potential prognostic factor and outcome as well as meeting  
149 the following eligibility criteria:

- 150 • The study included adults (aged 18 years or over), diagnosed with CTS in  
151 either a clinical setting or population setting. Studies in pregnant women and  
152 in populations such as specific occupational groups were excluded
- 153 • The study observed the course of CTS over at least a 6 week period in  
154 patients receiving no treatment or usual care that included conservative (non-  
155 surgical) treatments. Studies reporting risk factors for onset of CTS as  
156 opposed to predictors of outcome were excluded, as were studies  
157 investigating predictors of the effectiveness of a specific treatment (which

158 would ideally require a review of randomised clinical trials and is planned for  
159 the future)

- 160 • The design was of a longitudinal cohort study with either prospective or  
161 retrospective data collection
- 162 • There were no language restrictions and none of the research identified was  
163 only reported in abstract.

164 A systematic, computerised search of the literature was conducted in Medline,  
165 Embase, AMED, HMIC, PsychINFO, Cinahl, Cochrane, SCI-EXPANDED and CPCI-  
166 S from their inception until December 2013. The Medline search strategy can be  
167 found in Supplementary table S1. References of all included full-text articles were  
168 hand-searched and the first 15 pages of Google Scholar results for 'carpal tunnel  
169 syndrome' and 'prognosis' were screened as a further check for relevant hits.  
170 Experts were contacted to identify any further studies or publications in the grey  
171 literature that had not been identified in the search. The titles were screened by one  
172 reviewer (CB) and abstracts were screened by two reviewers (CB and LC) and full  
173 papers of potentially eligible studies retrieved. Such papers were screened by the  
174 two reviewers independently for eligibility and included in the review if they met the  
175 pre-specified criteria.

## 176 *2.2 Quality assessment*

177 All selected studies were assessed independently for quality by CB and LC using the  
178 Quality in Prognosis Studies (QUIPS) tool<sup>16</sup>. The QUIPS tool assesses bias in the  
179 six following domains: 1) study participation; 2) study attrition; 3) prognostic factor  
180 measurement; 4) outcome measurement 5) study confounding and 6) statistical  
181 analysis and reporting. Judgements of low, moderate or high risk of bias were made

182 for each applicable domain using descriptors recommended by Hayden et al <sup>16</sup>.  
183 Summated scores for overall study quality are not generally recommended, however  
184 assessment of the overall risk of bias is suggested to be useful when synthesising  
185 existing evidence <sup>16</sup>. Using suggestions from Hayden et al.,<sup>16</sup> studies were judged to  
186 be of low overall risk of bias if all or most of the domains were judged as low risk,  
187 and studies in which all or most of the domains were judged as high risk were  
188 considered to be of high overall risk of bias. Studies with a moderate risk of bias  
189 were those with all or most of the domains being judged as moderate risk of bias.  
190 Differences between reviewers were discussed and a decision made by agreement.  
191 Agreement between reviewers (CB and LC) regarding the judgement of overall risk  
192 of bias was presented as percentage agreement.

### 193 *2.3 Data extraction*

194 Data were extracted by CB and checked by LC. Data extraction included details of  
195 the study setting, population demographics, diagnostic criteria of CTS used,  
196 management approaches used, prognostic factors (type of factors and how  
197 measured), outcome measures (definition and instrument used), sample size, rate of  
198 attrition and length of follow up. With regard to clinical course, the percentage of  
199 patients with a negative outcome following conservative treatment or no treatment  
200 were recorded. All reported prognostic factors were listed and measures of  
201 association with their significance levels recorded.

### 202 *2.4 Analysis*

203 Results regarding the course of symptoms in patients with untreated and  
204 conservatively treated CTS were summarised narratively. Pooling of results was not  
205 possible due to heterogeneity with regard to study setting, case definition, follow-up

206 periods and measures of outcome. We summarised findings for the reported  
207 prognostic factors by taking into account the number of studies evaluating the factor,  
208 the risk of bias of these studies and the consistency of the available evidence (as  
209 defined as significant association with the same direction). A level of evidence was  
210 defined for each factor, based on Sackett et al. <sup>17</sup> and Ariens et al. <sup>18</sup> and adapted for  
211 use with the QUIPS tool (Table 1).

## 212 **Results**

### 213 *3.1 Selection of studies*

214 Figure 1 presents a flow chart of study selection. 15,572 citations were identified  
215 (6987 Medline, 6445 Embase, 197 AMED, 19 HMIC, 92 PsychINFO, 707 Cinahl, 755  
216 Cochrane, 370 SCI-EXPANDED and CPCI-S). Following the removal of duplicates  
217 and a screen of the titles, 146 abstracts were screened and 42 full text publications  
218 retrieved for further eligibility screening. 26 papers were excluded for the following  
219 reasons: one foreign language duplicate was found, 3 studies reported conditions  
220 not specific to CTS (i.e. wrist pain or unspecified entrapment neuropathies), 6  
221 studies reported outcomes in a specific population, 4 studies reported aetiology of  
222 CTS only, 6 studies reported on outcomes of specific treatments and 6 studies used  
223 a design other than that described in the selection criteria. 16 papers (reporting on  
224 16 cohorts) met all eligibility criteria and were included in the review.

### 225 *3.2 Study Characteristics*

226 Table 2 summarises the characteristics of the studies including the QUIPS score,  
227 study design and setting, study population, interventions used in the study, the  
228 primary outcome measure including the definition of a negative outcome, and

229 duration of follow-up. The table also presents the percentage of the cohort  
230 experiencing a negative outcome (e.g. surgery) of conservative or no management.  
231 One study was a retrospective follow-up study of cases identified in the Marshfield  
232 Epidemiologic Study Area, a population-based cohort <sup>19</sup>. All other studies were  
233 based in secondary or tertiary care, of which 6 were in surgical clinics and 8 in EMG  
234 (Electromyography) laboratories. No studies were based in primary care. The case  
235 definitions used to identify CTS differed: 6 studies used clinical features only whilst  
236 the remaining 10 studies required accompanying electrophysiological abnormality.  
237 The combination of clinical characteristics used and the electrophysiological criteria  
238 also varied between studies. The interventions used in the studies included; wrist  
239 splinting (7 studies), NSAIDS (non-steroidal anti-inflammatories) (3 studies), other  
240 analgesia (2 studies), oral steroids (3 studies), local steroid injections (6 studies) and  
241 paraffin treatment (1 study). Three studies provided conservative management  
242 without specifying which mode exactly. In 4 studies, the course of (clinically)  
243 untreated CTS was observed <sup>20-23</sup>. In some studies, parts of the cohort were treated  
244 surgically. Their specific outcomes were not included in this review. A range of  
245 outcome measures were used: 3 studies used a surgical episode as a proxy for a  
246 negative outcome; 1 study used the *Quickdash* score; 5 used measures of global  
247 improvement; 2 used a change in symptom and function severity scores; 1 used the  
248 Historic and Objective Scale <sup>24</sup>; 1 used work absence; 2 observed  
249 electrophysiological changes and 1 used absence of clinical contact as an indicator  
250 of recovery. The follow-up periods ranged from 12 weeks to 10 years.

251

### 252 3.3 Methodological quality

253 The results of the quality assessment are presented in Table 3. In 4 studies,  
254 investigating course of CTS symptoms only, the prognostic factor domain was not  
255 assessed. The percentage agreement between authors CB and LC, with regard to  
256 judgement of the overall risk of bias was 75% and 100% following discussion.  
257 Further adjudication was therefore not required.

258 Eight studies were judged to have a moderate risk of bias and 8 to have a high risk  
259 of bias. The domains that carried a particularly high risk of bias across all studies  
260 were: study attrition (12 studies); study confounding (10 studies) and statistical  
261 analysis and reporting (9 studies). Study attrition tended to be at high risk of bias as  
262 the response rates in several studies were low (see table 3), attempts to collect  
263 information on participants who dropped out was often lacking, reasons for loss to  
264 follow-up were rarely provided and differences between those lost to follow-up and  
265 those actively followed up were not frequently compared. Study confounding was  
266 also a frequent finding largely due to the fact that not all potential confounders were  
267 appropriately accounted for and hence the observed associations of the potential  
268 prognostic factors with outcome were likely to be at least partly explained by other  
269 (unmeasured) factors. This was particularly true in studies using retrospectively  
270 collected data. Statistical analysis and reporting was commonly identified as being  
271 of high risk of bias as presentation of the data was frequently insufficient and in  
272 some studies selective reporting of results was evident.

### 273 3.4 Course of carpal tunnel syndrome

274 For each included study, Table 2 describes results regarding the course of CTS in  
275 conservatively treated or untreated patients by describing the proportion of patients

276 who experience a negative outcome, the definition of which varied between studies  
277 (i.e. persisting or worsening symptoms, progression to surgery, or work absence due  
278 to CTS). Table 4 further summarises results regarding the course of CTS in terms of  
279 the percentage of patients reporting a negative outcome for different follow-up time  
280 points.

281 4 studies examined the course of untreated CTS<sup>20-23</sup>. OrizCorredor et al observed  
282 that of 132 patients with untreated CTS over a 2 year period, 23.5% showed a  
283 deterioration in the HiOb score but most cases did not show an electrophysiological  
284 deterioration (89 remained the same, 33 recovered and 10 deteriorated. Only 1  
285 patient had both an electrophysiological and clinical deterioration<sup>22</sup>. Padua 1998 et al  
286 reported whether the clinical outcome was unchanged or worse in groups of patients  
287 with different electrophysiological classifications. They found the clinical outcome  
288 was worse in 50% of patients with negative electrophysiology, 27.5% with moderate  
289 studies and 50% of extreme studies<sup>20</sup>. Padua 2001 et al further observed the  
290 electrophysiological, symptomatic, functional, HiOb and pain changes in patients  
291 with CTS. They reported that 16%, 21%, 16%, 32% and 12% of patients in each of  
292 these outcome areas worsened<sup>21</sup>, whilst 27%, 34%, 23%, 23% and 26% of patients  
293 improved<sup>21</sup>. Resende et al presented the change in electrophysiological measures  
294 and accompanying change in symptoms over a 4 to 9 year periods and found that  
295 25% of patients had a marked improvement in electrophysiological outcome (100%  
296 of whom had improvement in terms of symptoms); 15% showed slight improvement  
297 (of whom 33% had worsening of symptoms); 50% showed no significant change (of  
298 whom 50% had worsening in terms of symptoms) and 10% had a worsening of  
299 electrophysiological measurements (of whom 50% had a worsening of clinical  
300 symptoms)<sup>23</sup>. In summary, 32 - 58% of participants receiving no treatment were

301 reported to have a negative outcome at 12 months follow-up in two studies<sup>20, 21</sup>, both  
302 of which were of moderate risk of bias. The two further studies reporting at 3 and 10  
303 years were at high risk of bias and reported a negative outcome in 23.4%<sup>22</sup> and 50%  
304 <sup>23</sup>.

305 In the 9 cohorts receiving conservative treatment: 68.5% - 75% of patients were  
306 reported to have a negative outcome within 3 months follow-up<sup>25, 26</sup>; 82% within 6  
307 months<sup>27</sup>; 23 – 89% within 3 years<sup>19, 28-31</sup> and 22 – 24% within 10 years<sup>28, 32</sup>. A  
308 wide variation in findings was noted according to risk of bias, with studies of a  
309 moderate risk of bias appearing to show lower percentages of patients with a  
310 negative outcome (e.g. 23 – 68% at 3 years<sup>19, 28-30</sup>), compared to studies of high risk  
311 of bias (82% at 6 months<sup>27</sup> and 89% at 3 years<sup>31</sup>). Four studies used a surgical  
312 episode as a marker of negative outcome of conservative management<sup>27, 33-35</sup>. A  
313 range of 57% to 66% of patients were observed to receive surgery following  
314 conservative management over a period of between 1 and 3 years<sup>27, 33-35</sup>. In  
315 summary, the reported course of conservatively managed CTS is highly variable but  
316 symptoms do improve over time.

### 317 *3.5 Prognostic factors predicting negative outcome of carpal tunnel syndrome*

318 Eleven of the studies presented data on the association between potential prognostic  
319 factors and a negative outcome of conservatively managed CTS.

320 Table 5 presents potential prognostic factors observed in the studies and reported  
321 associations. Not all studies presented estimates of associations with confidence  
322 intervals. Some presented P values only; some simply reported a finding as non-  
323 significant. Therefore, the number of studies investigating each association, the



324 number of studies of moderate or high risk of bias (none were of low risk) and the  
325 number showing an association (direction and significance) are summarised.

326 In total 39 potential prognostic factors were identified from the studies. All of these  
327 were found to have inconclusive levels of evidence of an association with a negative  
328 outcome. This was due to inconsistencies in study findings, non-significant results,  
329 low numbers of studies investigating each factor and the moderate to high risk of  
330 bias of the studies included.

### 331 **Discussion**

332 This study is the first systematic review of the prognosis of conservatively managed  
333 CTS. A substantial amount of heterogeneity exists in terms of study setting, case  
334 definition, follow-up periods and measures of outcome between the included studies,  
335 which prevented meta-analysis from being conducted. A best evidence synthesis  
336 was therefore presented.

#### 337 *4.1 Course of carpal tunnel syndrome*

338 Four studies observed the course of untreated CTS<sup>20-23</sup>, which is helpful when  
339 considering the need for or impact of treatment. These studies suggest that a  
340 proportion (28% - 62%)<sup>20-23</sup> of patients will recover or not deteriorate further in the  
341 absence of treatment and hence a certain period of 'watchful waiting' (not clearly  
342 defined by the available evidence) may be considered clinically when discussing  
343 treatment options with patients. When considering potential mechanisms for  
344 recovery (not including mechanisms of treatment) Padua et al 1998 suggest that  
345 certain undefined CTS cases are self-limiting due to a process of neural adaption,

346 whereby the functional relationship between the nerve and the carpal tunnel adapts  
347 over time<sup>20</sup>.

348 Due to outcomes being measured at discrete time points by each study, it was not  
349 possible to provide a cumulative percentage of patients recovering in each period  
350 and so provide clearer information about what is happening to patients with CTS  
351 over time. Table 4 does however show that a proportion of patients can be observed  
352 to have deteriorated from baseline at any point between 3 months and 10 years,  
353 suggesting that the course of CTS is likely to be highly variable. It is possible that the  
354 studies with longer follow up periods may be representative of patients who improve  
355 and relapse over time, but as none of the studies were designed to observe the  
356 longitudinal course of CTS (i.e. at a week-to-week or month-to-month level), such a  
357 symptom course could not be illustrated by this review.

358 With regard to symptom relapse, only one study<sup>31</sup> specifically addressed this issue.  
359 Goodwill et al reported that 85% of patients initially responding to conservative  
360 treatment approaches relapsed within 1 to 4 years<sup>31</sup>. The possibility of future relapse  
361 therefore puts into question the observations of all studies conducted over a shorter  
362 time frame. A further consideration is that a recurrence of symptoms following a  
363 conservative treatment which then responds to a further episode of conservative  
364 management (if deemed clinically appropriate), may not necessarily represent  
365 treatment failure. However, longitudinal data which may describe this phenomenon  
366 was not available, again emphasising the importance of long-term studies with  
367 repeated assessment of symptoms in patients with CTS.

368 The observed between-study variability may be partially explained by substantial  
369 differences in study setting, study design, case definitions, interventions (the

370 effectiveness of which cannot be compared between studies), and outcomes used  
371 but possibly also by differences in patient or disease factors (potential prognostic  
372 factors) between studies.

373 *4.2 Prognostic factors predicting negative outcome of conservatively managed*  
374 *carpal tunnel syndrome*

375 Due to inconsistencies between study findings and the lack of studies with a low risk  
376 of bias, it was not possible to identify conclusive evidence for any of the factors  
377 reported by individual studies to predict a negative outcome of conservative  
378 management.

379 There was however 100% agreement in at least 3 or more cohorts with a medium or  
380 high risk of bias that: symptom duration; a positive Phalen's test; and thenar wasting  
381 were associated with a negative outcome of conservative management, however not  
382 all results were statistically significant and hence the overall judgement remained  
383 inconclusive.

384 Due to a lack of robustness in design and conduct of most of the included studies,  
385 the overall body of evidence identified was felt to be of moderate and high risk of  
386 bias. This limited whether the synthesised evidence could be considered as  
387 conclusive and as such evidence regarding the prognosis of untreated and  
388 conservatively treated CTS remains weak. To improve future research key  
389 recommendations would include identifying patients with CTS at baseline using a  
390 robust case definition of the condition. Patients should be followed up for a  
391 prolonged period (over 3 years), preferably at a number of time points using a  
392 clinically meaningful, valid and reliable outcome measure. This would allow a  
393 longitudinal picture of CTS to be mapped. Attempts could be made to reduce

394 attrition or better describe the risk of attrition bias by collecting information from non-  
395 responders and to provide a description and reason for any loss to follow up. Ideally,  
396 all potential prognostic factors should be included and measured at baseline using  
397 valid and reliable measures<sup>16</sup>.

398 To capture the start point of the condition and its earliest management, it would be  
399 beneficial to set such a study in primary care, where it is likely most patients present  
400 initially with their symptoms and commence treatment.

#### 401 *4.3 Limitations*

402 We searched electronic databases considered to be important and relevant to the  
403 topic. Titles were screened by one person due to the significant number; hence  
404 human error may have led to some titles being missed. Studies not included in  
405 databases and not identified through reference checking, Google Scholar and expert  
406 advice may have been overlooked, such as unpublished cohort studies. As the  
407 review did not find strong evidence for any of the prognostic factors, it is unlikely that  
408 further unpublished material would have strongly influenced our conclusions. The  
409 review focussed on studies observing the course of symptoms in patients being  
410 treated conservatively for CTS but excluded cohorts being allocated specific  
411 treatments. Predictors of differential treatment response (moderators) are best  
412 identified by randomised trials and as such a further systematic review of these  
413 studies is planned.

414 Results of studies presenting only descriptive results and P-values were included in  
415 the review, without any risk estimates. All evidence found could therefore be  
416 included but there is a possibility that the lack of statistical significance was due to  
417 small sample sizes and hence represent a lack of evidence for some of the

418 prognostic factors rather than a genuine absence of association. Future prognosis  
419 research in the area of CTS should therefore ensure that estimates of associations  
420 with outcome are adequately reported and that the study population is of adequate  
421 sample size to investigate the hypothesised associations with outcome.

422 The unit of analysis differed between studies i.e. some analysed outcomes at patient  
423 level (not necessarily taking into account the laterality of the condition); whilst others  
424 analysed outcomes at wrist level (i.e. patients with bilateral symptoms may be  
425 included as 2 cases, not taking dependence of outcomes within individuals into  
426 account). Issues relating to the statistical analysis of bilateral CTS has been  
427 discussed at length for clinical trials by Page et al<sup>36</sup>. A unit-of-analysis error, which  
428 may give rise to overly narrow confidence intervals and small P values, may occur  
429 when data is analysed on the basis of the number of wrists without adjustment for  
430 non-independence<sup>36</sup>. Such an error may also occur in prognosis research, including  
431 the reviewed studies, and be a further source of bias. Future prognostic studies  
432 should, where possible, take into consideration this risk of bias in their design and  
433 analysis plan.

#### 434 *4.4 Implications for clinical practice*

435 Patients presenting with CTS can be informed of the possibility of recovery with no  
436 treatment or conservative treatment i.e. that they will not require surgery, however  
437 factors which help to predict their likelihood of falling into this group have not been  
438 robustly determined. Increasing symptom duration, positive Phalen's test and thenar  
439 atrophy are likely to be prognostic factors of poor outcome of conservatively  
440 managed CTS but need confirmation in further well-designed prognostic studies. The  
441 review did not identify electrophysiological severity as a significant predictor of a

442 negative outcome of conservative management. This may have implications for  
443 services which ration surgery to patients with more severe results and suggest other  
444 factors should be taken into consideration alongside laboratory investigations.

#### 445 **Conclusion**

446 In this review we found useful descriptions of both the course of untreated CTS and  
447 that of conservatively managed CTS. Although none of the studies were of low risk  
448 of bias, studies of moderate and high risk of bias showed a widely ranging course of  
449 symptoms, with 23 – 89% of participants reporting negative outcome at 3 years  
450 follow-up. We found no consistent evidence to support factors which predict future  
451 outcome and may help to explain the wide variability in the course of symptoms.

452 There is likely to be an optimum time by which conservative management should be  
453 deemed to have failed and surgical intervention considered, in order to prevent long  
454 term harm, although this point has not been clearly determined nor is it clearly  
455 possible to predict which patients may be included in this group.

#### 456 **References**

- 457 1. Alfonso C, Jann S, Massa R, Torreggiani A. Diagnosis, treatment and follow-up of  
458 the carpal tunnel syndrome: A review. *Neurol Sci.* 2010 Jun;31(3):243-52.
- 459 2. Aroori S, Spence RA. Carpal tunnel syndrome. *Ulster Med J.* 2008 Jan;77(1):6-17.
- 460 3. Ibrahim I, Khan WS, Goddard N, Smitham P. Carpal tunnel syndrome: A review of  
461 the recent literature. *Open Orthop J.* 2012;6:69-76.
- 462 4. Bland JDP, Rudolfer SM. Clinical surveillance of carpal tunnel syndrome in two  
463 areas of the united kingdom, 1991–2001. *Journal of Neurology, Neurosurgery &*  
464 *Psychiatry.* 2003 December 01;74(12):1674-9.

- 465 5. Atroshi I, Englund M, Turkiewicz A, TÅgil M, Petersson IF. Incidence of  
466 physician-diagnosed carpal tunnel syndrome in the general population. Arch Intern  
467 Med. 2011;171(10):943-5.
- 468 6. Gelfman R, Melton LJ,3rd, Yawn BP, Wollan PC, Amadio PC, Stevens JC. Long-  
469 term trends in carpal tunnel syndrome. Neurology. 2009 Jan 6;72(1):33-41.
- 470 7. Page MJ, Massy-Westropp N, O'Connor D, Pitt V. Splinting for carpal tunnel  
471 syndrome. Cochrane Database Syst Rev. 2012 Jul 11;7:CD010003.
- 472 8. Huisstede BM, Hoogvliet P, Randsdorp MS, Glerum S, van Middelkoop M, Koes  
473 BW. Carpal tunnel syndrome. part I: Effectiveness of nonsurgical Treatments–A  
474 systematic review. Arch Phys Med Rehabil. 2010 7;91(7):981-1004.
- 475 9. Carpal tunnel syndrome [homepage on the Internet]. . 2012. Available from:  
476 <http://cks.nice.org.uk/carpal-tunnel-syndrome#!scenariorecommendation:1>.
- 477 10. Carpal tunnel syndrome (CTS) - the map of medicine [homepage on the  
478 Internet]. . 2012 25/07/2012. Available from:  
479 [http://app.mapofmedicine.com/mom/127/page.html?department-id=8&specialty-](http://app.mapofmedicine.com/mom/127/page.html?department-id=8&specialty-id=1037&pathway-id=3411&page-id=8741&history=clear)  
480 [id=1037&pathway-id=3411&page-id=8741&history=clear](http://app.mapofmedicine.com/mom/127/page.html?department-id=8&specialty-id=1037&pathway-id=3411&page-id=8741&history=clear).
- 481 11. AAOS guideline on the treatment of carpal tunnel syndrome 2011 report for the  
482 "re-issue" of the original guideline<br /> [homepage on the Internet]. . 2011.  
483 Available from:  
484 [http://www.aaos.org/Research/guidelines/CTS\\_Treatment\\_REIssue.pdf](http://www.aaos.org/Research/guidelines/CTS_Treatment_REIssue.pdf).

- 485 12. O'Connor D, Marshall SC, Massy-Westropp N, Pitt V. Non-surgical treatment  
486 (other than steroid injection) for carpal tunnel syndrome. Cochrane Database of  
487 Systematic Reviews. 2003(1):CD003219-NaN.
- 488 13. Marshall S, Tardif G, Ashworth N. Local corticosteroid injection for carpal tunnel  
489 syndrome. Cochrane database of systematic reviews (Online). 2007  
490 2007(2):001554.
- 491 14. Harry Hemingway, Peter Croft, Pablo Perel, Jill A Hayden, Keith Abrams, Adam  
492 Timmis, et al. Prognosis research strategy (PROGRESS) 1: A framework for  
493 researching clinical outcomes. BMJ. 2013 BMJ Publishing Group Ltd;346.
- 494 15. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al.  
495 Prognosis research strategy (PROGRESS) 2: Prognostic factor research. PLoS  
496 Med. 2013 Feb;10(2):e1001380.
- 497 16. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing  
498 bias in studies of prognostic factors. Ann Intern Med. 2013 Feb 19;158(4):280-6.
- 499 17. Sackett DL, Straus SE, Richardson WS. Evidence-based medicine. how to  
500 practice and teach EMB. Edinburgh: Churchill Livingstone; 2000.
- 501 18. Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G. Physical  
502 risk factors for neck pain. Scandinavian Journal of Work, Environment and Health.  
503 2000;26:7-19.
- 504 19. DeStefano F, Nordstrom DL, Vierkant RA. Long-term symptom outcomes of  
505 carpal tunnel syndrome and its treatment. Journal of Hand Surgery - American  
506 Volume. 1997 Mar [cited 19970724];22(2):200-10.



- 507 20. Padua L, Padua R, Lo Monaco M, Aprile I, Paciello N, Nazzaro M, et al. Natural  
508 history of carpal tunnel syndrome according to the neurophysiological classification.  
509 Ital J Neurol Sci. 1998 Dec [cited 20000830];19(6):357-61.
- 510 21. Padua L, Padua R, Aprile I, Pasqualetti P, Tonali P. Multiperspective follow-up of  
511 untreated carpal tunnel syndrome: A multicenter study. Neurology.  
512 2001;56(11):1459-67.
- 513 22. OrtizCorredor F, Enriquez F, DiazRuiz J, Calambas N. Natural evolution of carpal  
514 tunnel syndrome in untreated patients. Clinical Neurophysiology. Jun  
515 2008;119(6):1373-8.
- 516 23. Resende LAL, Tahara A, Fonseca RG, Sardenberg T. The natural history of  
517 carpal tunnel syndrome: A study of 20 hands evaluated 4 to 9 years after initial  
518 diagnosis. Electromyogr Clin Neurophysiol. 2003 July/August 2003;43(5):301-4.
- 519 24. Gianinni F. Quantative assessment of historical and objective findings: A new  
520 clinical severity scale of CTS. In: Luchetti R, Amadio P, editors. Carpal Tunnel  
521 Syndrome. Springer Berlin Heidelberg; 2007. p. 82-8.
- 522 25. Lian BT, Urkude R, Verma KK. Clinical profile, electrodiagnosis and outcome in  
523 patients with carpal tunnel syndrome: A singapore perspective. Singapore Med J.  
524 2006 December 2006;47(12):1049-52.
- 525 26. Kiylioglu N, Bicerol B, Ozkul A, Akyol A. Natural course and treatment efficacy:  
526 One-year observation in diabetic and idiopathic carpal tunnel syndrome. Journal of  
527 Clinical Neurophysiology. 2009;26(6):446-54.

- 528 27. Kaplan SJ, Glickel SZ, Eaton RG. Predictive factors in the non-surgical treatment  
529 of carpal tunnel syndrome. *Journal of Hand Surgery - British Volume*. 1990 Feb  
530 [cited 19900406];15(1):106-8.
- 531 28. Muhlau G, Both R, Kunath H. Carpal tunnel syndrome--course and prognosis. *J*  
532 *Neurol*. 1984 [cited 19840731];231(2):83-6.
- 533 29. Katz JN, Lew RA, Besette L, Punnett L, Fossel AH, Mooney N, et al.  
534 Prevalence and predictors of long-term work disability due to carpal tunnel  
535 syndrome. *Am J Ind Med*. 1998 Jun [cited 19980720];33(6):543-50.
- 536 30. Katz JN, Keller RB, Simmons BP, Rogers WD, Besette L, Fossel AH, et al.  
537 Maine carpal tunnel study: Outcomes of operative and nonoperative therapy for  
538 carpal tunnel syndrome in a community-based cohort. *Journal of Hand Surgery -*  
539 *American Volume*. 1998 Jul [cited 19981014];23(4):697-710.
- 540 31. Goodwill CJ. THE CARPAL TUNNEL SYNDROME. LONG-TERM FOLLOW-UP  
541 SHOWING RELATION OF LATENCY MEASUREMENTS TO RESPONSE TO  
542 TREATMENT. *Ann Phys Med*. 1965 Feb [cited 19650501];8:12-21.
- 543 32. Kouyoumdjian JA, Morita MPA, Molina AFP, Zanetta DMT, Sato AK, Rocha  
544 CED, et al. Long-term outcomes of symptomatic electrodiagnosed carpal tunnel  
545 syndrome. *Arq Neuropsiquiatr*. 2003;61(2 A) (pp 194-198):ate of Pubaton: June  
546 2003.
- 547 33. Boyd KU, Gan BS, Ross DC, Richards RS, Roth JH, MacDermid JC. Outcomes  
548 in carpal tunnel syndrome: Symptom severity, conservative management and  
549 progression to surgery. *Clinical & Investigative Medicine*. 2005;28(5):254-61.

550 34. Duckworth AD, Jenkins PJ, Roddam P, Watts AC, Ring D, McEachan JE. Pain  
551 and carpal tunnel syndrome. Journal of Hand Surgery - American Volume. 2013 Aug  
552 [cited 20130729];38(8):1540-6.

553 35. Miranda BH, Asaad K, Cerovac S. Carpal tunnel syndrome study: Local  
554 corticosteroids, conversion to surgery and NHS implications. Journal of Plastic  
555 Reconstructive and Aesthetic Surgery. 2013 OCT;66(10):1432-3.

556 36. Page MJ, O'Connor DA, Pitt V, Massy-Westropp N. Reporting of allocation  
557 method and statistical analyses that deal with bilaterally affected wrists in clinical  
558 trials for carpal tunnel syndrome. Am J Phys Med Rehabil. 2013 Nov;92(11):1012-9.

#### 559 **Legends of Figures and Tables**

560 Table 1 Levels of evidence for prognostic factors<sup>17, 18</sup>

561 Table 2 Summary of study characteristics and results regarding the course of  
562 symptoms of prognostic cohort studies in carpal tunnel syndrome

563 Table 3 Results of the methodological assessment of prognostic cohort studies on  
564 CTS

565 Table 4 Course of carpal tunnel syndrome in conservatively treated or untreated  
566 patients (percentages not cumulative)

567 Table 5 Prognostic factors and strength of association for an unfavourable outcome  
568 of carpal tunnel syndrome in patients who are **conservatively treated or untreated**

569 Figure 1 Study selection

570

571

Table 1 Levels of evidence for prognostic factors<sup>17, 18</sup>

---

<b>Level of evidence</b>	
<b>Strong</b>	Consistent findings ( $\geq 75\%$ ) in at least 2 cohorts with a low risk of bias
<b>Moderate</b>	Consistent findings ( $\geq 75\%$ ) in one cohort with a low risk of bias and at least one cohort with a moderate/high risk of bias
<b>Weak</b>	Findings of one cohort with a low risk of bias or consistent findings ( $\geq 75\%$ ) in at least 3 or more cohorts with a moderate / high risk of bias
<b>Inconclusive</b>	Inconsistent findings irrespective of study quality, or less than 3 cohorts with a moderate / high risk of bias
<b>No evidence</b>	No data presented

---

- 1 Table 2 Summary of study characteristics and results regarding the course of symptoms of prognostic cohort studies in carpal
- 2 tunnel syndrome

Author (Year)	Risk of bias (QUIPS score)	Study population	Interventions provided to entire cohort	Primary outcome measure / duration follow - up	Measure of negative outcome of <b>conservative management</b>	Proportion of patients <b>treated conservatively</b> experiencing negative outcome
<b>Treated populations: prospective cohort studies</b>						
<b>Boyd et al. 2005<sup>33</sup></b>	High	Setting: tertiary hand and upper limb	Splint: all wrists  Surgery: 27	No surgery versus surgery by 6 months	Progression to surgery	57% of wrists

<b>Canada</b>		centre  CTS diagnosis: clinical findings and electrophysiological abnormality  68% female  Mean age: 49.3 years  N=25 patients	(57%) wrists	12 weeks, with an option to continue follow-up >6 months		
---------------	--	---	--------------	--	--	--

		(47 wrists)  Drop-out =  17%				
<b>Duckworth et al. 2013<sup>34</sup></b>	Moderate	Setting: hand clinic  CTS diagnosis: clinical findings and electrophysiological abnormality	Splint: all patients  Injection: 150 (55%) (of whom 38 had surgery)  Surgery: 122	<i>QuickDASH</i> Score  1 year	Progression to surgery	58% of patients

		<p>67% female (44%) patients</p> <p>Mean age: males 57 (s.d. 14) years; females 54 (s.d. 14) years</p> <p>N=275 patients</p> <p>Drop-out = 28%</p>	<p>No further treatment: 3 (1%) patients</p>			
<b>Goodwill.</b> <b>1965<sup>31</sup></b>	High	Setting: EMG laboratory	Splint: 98 (63%) wrists	Judgement made at follow-up: cured,	Evidence of symptoms	Following steroid injection: 88%



<p><b>England</b></p>		<p>CTS diagnosis: paraesthesia and pain with electrophysiological abnormality</p> <p>93% female</p> <p>Age bands:</p> <p>30-39: 7</p> <p>40-49: 19</p> <p>50-59: 39</p> <p>60-69: 18</p>	<p>Injection: 58 (37%) wrists</p> <p>Surgery: 55 (35%) wrists</p>	<p>temporary relief or no relief</p> <p>1 - 3 years (average 14 months)</p>		<p>of patients</p> <p>Following splinting: 89% of patients</p> <p>Following surgery: 5% of patients</p>
-----------------------	--	--	---	---	--	---

		70+: 13 patients  N=96 patients (155 wrists)  Drop-out = 0%				
<b>Kaplan, Glickel &amp; Eaton. 1990<sup>27</sup></b>  <b>USA</b>	High	Setting: hand clinic  CTS diagnosis: presence of pain or paraesthesia and clinical	Splint: 'most patients'  Non-steroidal anti-inflammatory:	Success of therapy as defined by absence of symptoms for > 6 months	Evidence of symptoms after 6 months  Progression to surgery	82% of wrists  66% of wrists

	findings (thenar atrophy, altered sensation or Phalen's sign)	149 (65.2%) patients	Minimum of 6 months or until had surgical release (average 15.4 months)		
	75% female	Oral steroid: 61 (26.8%) patients			
	Mean age 55 years	Steroid injection: 38 (16.4%) patients			
	N = 229 patients (331 wrists)				
	Drop-out =				

		12%				
<b>Katz et al.</b> <b>1998 a<sup>30</sup></b>  <b>USA</b>	Moderate	Setting: surgical clinics  CTS diagnosis: paraesthesia involving at least 2 digits (thumb or index, middle or ring fingers) and symptom duration of at least 1 month	Non-surgical cohort: 34 patients received surgery at less than 3 months and were not included in analyses  By 30 months:  Splint: 76	Change in status in symptom severity, functional limitations and health status were recorded over time. Associations were measured for patients crossing	Would not be happy to live the rest of their lives with symptoms	60% of patients

		<p>74% female</p> <p>Surgical cohort: &gt;55yr mean age 68.0 years (sd 9.1); &lt;55yr compensation non recipient 42.0 years (sd 7.3); compensation recipient mean age 39.0 years (sd 8.1).</p>	<p>(94%) patients</p> <p>Injection: 36 (44%) patients</p> <p>Physical or occupational therapist: all</p>	<p>between non-surgical to surgical cohorts after &gt; 3 months.</p> <p>Follow up took place at 6, 18 and 30 months</p>		
--	--	--	--	---	--	--

		<p>Non-surgical cohort &gt;55yr mean age 64.0 years (sd 7.0); compensation non-recipient mean age 41.0 (sd 8.9); compensation recipient mean age 37.0 years (sd 8.8)</p> <p>N = 297 patients</p>				
--	--	--	--	--	--	--

		Drop-out = 31%				
<b>Kiylioglu et al.</b>  <b>2009<sup>26</sup></b>  <b>Turkey</b>	Moderate	Setting: EMG laboratory  CTS diagnosis: clinical findings, supported by electrophysiological abnormality.  90% female	Treatment methods not controlled or standardised  'Rehabilitation': patients treated with splints, paraffin treatments and / or oral non-	Symptom severity score and functional status (Boston questionnaire translated into Turkish)  Patients were followed up in the early	Percentage improvement in symptom severity scale  Percentage improvement in function severity scale	Rehabilitation 82  Surgery 77  Untreated 25  Rehabilitation 73

		Diabetic rehabilitation group mean age 59.3 years (sd 7.4); diabetic untreated group mean age 54.6 (sd 11.1); idiopathic rehabilitation group mean age 47.8 years (sd 9.9); idiopathic	steroidal anti-inflammatory	follow-up period (3-5 months) and late follow up period (6-12 months)		Surgery 85 Untreated 17
--	--	--	-----------------------------	---	--	----------------------------------



		<p>surgery group</p> <p>mean age 49.2 (sd 9.8)</p> <p>N = 42 patients (80 wrists)</p> <p>Drop-out = 0 (assumed)</p>				
<b>Treated populations: retrospective cohort studies</b>						
<b>Kouyoumdjian et al. 2003<sup>32</sup></b>	High	<p>Setting: EMG laboratory</p> <p>CTS diagnosis:</p>	<p>Surgery: 147 (66%) wrists</p>	<p>General patient satisfaction:</p> <p>complete relief; improved</p>	<p>Symptoms unchanged or worse</p>	<p>23.7% of wrists</p>

<b>Brazil</b>		<p>symptoms including hand paraesthesia, numbness and pain mainly at night.</p> <p>95.8% female</p> <p>Surgical cure group mean age 46 years (range 24 – 70); unchanged / worse group 44</p>	<p>Non-surgical (splint, local injection, medication and others): 75 (34%) wrists</p>	<p>“much better”; improved</p> <p>“little”; unchanged; worsened</p> <p>Poorly recorded.</p> <p>Between 5-10 years, (mean 5.9 years following surgery)</p>		
---------------	--	--	---	---	--	--

		<p>years (range 39 – 58); non-surgical cure group mean age 61 years (range 48 – 79); worse group 50 years (range 30 – 83)</p> <p>N = 165 patients (222 wrists)</p> <p>Drop-out =</p>				
--	--	--	--	--	--	--

		69%				
<b>Lian, Urkunde &amp; Verma. 2006<sup>25</sup>  Singapore</b>	High	Setting: EMG laboratory  CTS diagnosis: clinical history and examination, confirmed using AAEM criteria and additional testing if this was normal	Conservative management:  88 (77%) patients  Surgery: 27 (23%) patients	Clinician review of medical records and decision made as to category: resolved; improved; same; worse  Follow up took place at 3 and	Symptoms unchanged or worse	68.5% of patients

		81.3% female  Mean age 53.6 years  N = 115  Drop-out 14%		6 months  (limited data available)		
<b>Miranda, Asaad &amp; Cerovac. 2013<sup>35</sup></b>	High	Setting: plastic surgery clinic  CTS diagnosis: based on clinical	Injection: 66 (49%) patients  Surgery: 68	Symptom relief and / or surgery  22.5 +/- 0.5	Progression to surgery	62% of patients

UK		symptoms  Gender not reported  Mean age 56 years (sd 3)  N = 134  Drop-out 10%	(51%) patients	months		
<b>Muhlau, Both &amp; Kunath.</b>	Moderate	Setting: EMG laboratory  CTS diagnosis:	Conservative management:  72 (48%) wrists	An overall categorisation was made at	No evidence of cure	68% of patients

<p>1984<sup>28</sup></p> <p>Germany</p>		<p>distal motor latency was &gt;4.7ms</p> <p>Gender and age not reported</p> <p>N = 157 (214 wrists)</p> <p>Drop-out 38%</p>	<p>Surgery: 112 (52%) wrists</p>	<p>follow up: cured; clear improvement; slight improvement; unchanged findings; further deterioration.</p> <p>These were then dichotomised so that groups 1 and 2 = cured and 3,4 and 5 = not</p>		
---	--	--	----------------------------------	---	--	--

				cured.  Follow up was at least 2 years and defined as when the patient had reached a 'steady state'		
<b>Treated populations:</b> Retrospective follow-up study of a population-based case series						
<b>DeStefano, Nordstrom &amp; Vierkant.</b>	Moderate	Setting: patients identified from	Analgesia: 143 (34%) patients	No surgery versus surgery and resolution	Evidence of symptoms	1 month: 75% of patients



<p><b>1997<sup>19</sup></b></p> <p><b>USA</b></p>		<p>the Marshfield Epidemiologic Study Area</p> <p>CTS diagnosis: ICD-9-CM code 354.0 and evidence of a clinical and / or electrophysio- logical abnormality in the records.</p> <p>62% female</p>	<p>Non-steroidal anti- inflammatories: 132 (31%) patients</p> <p>Injection: 6 (1%) patients</p> <p>Splint: 295 (69%) patients</p>	<p>of symptoms</p> <p>Median follow- up 1979 - 1983: 12.0 years (5 and 95th percentiles:10. 0 and 14.8 respectively). 184-1988: 7.3 years (5.0-9.8)</p>	<p>2 years: 40%</p> <p>8 years: 22%</p>
---	--	---	---	---	---

		Mean age 62 years  N= 425  Drop-out 0%	Surgery: 198 (47%) patients			
<b>Treated populations:</b> Secondary analysis of Katz et al.1998 a						
<b>Katz et al 1998 b<sup>29</sup>  USA</b>	Moderate	Setting: surgical clinics  CTS diagnosis: paraesthesia involving at least 2 digits	Surgery: 179 (71%) patients	Out of work at 18 months  Questionnaires were completed at 6,	Work absence at 18 months, due to CTS	23% of patients

		(thumb or index, middle or ring fingers) and symptom duration of at least 1 month  72% female  Mean age 43 years (sd 11)  N= 253 patients  Drop-out =		18 and 30m		
--	--	--	--	------------	--	--

		20%				
<b>Untreated populations: prospective cohort studies</b>						
<b>OrtizCorredor et al. 2008<sup>22</sup></b>	High	Setting: EMG laboratory  CTS diagnosis: as per Rempel et al  81.1% female  Mean age 48.8 years (sd 10.2)	The course of untreated CTS was observed	The Historic and Objective Scale (HiOb) was used as the clinical classification.  The electrophysiological classification was according to Padua 1997	Deterioration in the Historic and Objective Scale	23.4% of patients

		N = 132 patients  Not possible to determine drop-out		(mild; moderate A; moderate B; Severe; Extreme)  24.2 months (sd 4.2)		
<b>Padua et al.</b>  <b>1998<sup>20</sup></b>  <b>Italy</b>	Moderate	Setting: EMG laboratory  CTS diagnosis: based on neurophysiolog ical evaluation	The course of untreated CTS was observed	Patient reported global improvement scale: stable, worse, improved	Clinical outcome: unchanged	Neurophysiolog ical classification  Negative 50%  Minimal 38%

		<p>graded: negative, minimal, mild, moderate, severe and extreme (Padua et al).</p> <p>78.8% female</p> <p>Mean age 48.8 years (sd 10.2)</p> <p>N = 80</p>		<p>Neurophysiolo gical classification: negative, minimal, mild, moderate, severe, extreme</p> <p>11.6 months (range 5-23)</p>	<p>Clinical outcome: worse</p>	<p>Mild 15%</p> <p>Moderate 27.5%</p> <p>Severe 0%</p> <p>Extreme 50%</p> <p>Negative 50%</p> <p>Minimal 31%</p> <p>Mild 58%</p> <p>Moderate 45%</p> <p>Severe 20%</p> <p>Extreme 0%</p>
--	--	--	--	---	--	--

		Drop-out 84%				
<b>Padua et al.</b>  <b>2001</b> <sup>21</sup>  Italy	Moderate	Setting: EMG laboratory  CTS diagnosis: based on clinical diagnostic criteria proposed by the American Academy of Neurology and the American Association of Electrodiagnost	The course of untreated CTS was observed	Electrophysiological changes, patient reported changes and clinical changes were used to describe if patients had: improved, remained stationary or worsened.	Neurophysiological class  Symptoms  Function  Historic and	Stationary 57%  Worsening 16%  Stationary 45%  Worsening 21%  Stationary 61%

		ic Medicine		10 - 15 months	objective scale	Worsening 16%
		82% female			Pain	Stationary 46%
		Mean age 52.0 years (sd 13.4)				Worsening 32%
		N = 202 (267 wrists) with a further 62 (87 wrists) re- evaluated by phone				Stationary 62%
		Drop-out 34%				Worsening 12%



<b>Untreated populations: retrospective cohort studies</b>						
<b>Resende et al.</b>  <b>2003<sup>23</sup></b>  <b>Brazil</b>	High	Setting: EMG laboratory  CTS diagnosis: clinical findings, supported by electrophysiological abnormality  Patients in an EMG lab with a	The course of untreated CTS was observed	Clinical and electrophysiological changes were observed.  4 – 9 years	Conduction studies	Marked improvement 25% (of which 100% had improvement in symptoms)  Slight improvement 15% (of which 33% had worsening of clinical

		diagnosis of CTS based on.  N=12  Drop-out not possible to determine				symptoms)  No significant change 50% (of which 50% had worsening of clinical symptoms)  Worsening 10% (of which 50% had worsening of clinical symptoms)
--	--	---	--	--	--	---

Table 3 Results of the methodological assessment of prognostic cohort studies on CTS

Author (year)	1. Study Participation	2. Study Attrition	3. Prognostic Factor Measurement	4. Outcome Measurement	5. Study Confounding	6. Statistical Analysis and Reporting	Overall Risk of bias
<b>Studies including an analysis of prognostic factors</b>							
<b>Boyd et al. 2005<sup>33</sup></b>	High	High	Moderate	Moderate	Moderate	High	<b>High</b>
<b>DeStefano, Nordstrom &amp; Vierkant. 1997<sup>19</sup></b>	Low	Moderate	Moderate	Moderate	Moderate	Moderate	<b>Moderate</b>

---

<b>Duckworth et al. 2013<sup>34</sup></b>	Moderate	High	Moderate	Moderate	High	Low	<b>Moderate</b>
<b>Goodwill. 1965<sup>31</sup></b>	High	High	High	High	High	High	<b>High</b>
<b>Kaplan, Glickel &amp; Eaton. 1990<sup>27</sup></b>	High	High	High	High	High	High	<b>High</b>
<b>Katz et al. 1998a<sup>30</sup></b>	Low	Moderate	Moderate	Moderate	Low	High	<b>Moderate</b>
<b>Katz et al 1998b<sup>29</sup></b>	Low	High	Moderate	Low	High	Low	<b>Moderate</b>
<b>Kiylioglu et al. 2009<sup>26</sup></b>	Moderate	High	Moderate	Moderate	Moderate	High	<b>Moderate</b>

---

<b>Kouyoumdjian et al. 2003<sup>32</sup></b>	Moderate	High	Moderate	Moderate	High	High	<b>High</b>
<b>Muhlau, Both &amp; Kunath. 1984<sup>28</sup></b>	Moderate	High	Low	Moderate	Moderate	Low	<b>Moderate</b>
<b>Padua et al. 2001<sup>21</sup></b>	Low	Moderate	Low	Moderate	Moderate	Moderate	<b>Moderate</b>
<b>Studies observing the course of CTS only (with no analysis of prognostic factors)</b>							
<b>Lian, Urkunde &amp; Verma. 2006<sup>25</sup></b>	High	High	Not applicable	High	High	High	<b>High</b>
<b>Miranda, Asaad &amp;</b>	High	High	Not applicable	High	High	High	<b>High</b>

---

**Cerovac.**

**2013<sup>35</sup>**

**OrtizCorredor**      Moderate      Moderate      Not applicable      Low      High      High      **High**

**et al. 2008<sup>22</sup>**

**Padua et al.**      High      High      Not applicable      Low      High      Low      **Moderate**

**1998<sup>20</sup>**

**Resende et al.**      High      High      Not applicable      High      High      Moderate      **High**

**2003<sup>23</sup>**

---

Table 4 Course of carpal tunnel syndrome in conservatively treated or untreated patients (percentages not cumulative)

Number of studies	Sample size range	% of cases reporting deterioration within 3 months	% of cases reporting deterioration within 6 months	% of cases reporting deterioration within 12 months	% of cases reporting deterioration within 3 years	% of cases reporting deterioration within 5 years	% of cases reporting deterioration within 15 years
Untreated cases							
4 <sup>20-23</sup>	12 – 344			32 - 58	23.4		50
Studies observing cases receiving surgery as a consequence of conservative management failure (% of patients receiving surgery NOT outcome of surgery)							
4 <sup>27, 33-35</sup>	47 - 331		57	58	62 - 66		

Studies of conservatively managed patients reporting other definitions of negative outcome							
9 <sup>19, 25-</sup> 32	80 - 425	68.5 - 75	82	% <i>improvement of up to 82%</i> *	23 - 89		22 - 23.7
<p>The percentages shown are not cumulative as it cannot be assumed that patients reporting a change in symptoms at 6 months, would not have reported something different at an earlier or later date if the study had provided them with such opportunity</p> <ul style="list-style-type: none"> <li>• % change provided in positive direction<sup>26</sup></li> </ul>							



Table 5 Prognostic factors and strength of association for an unfavourable outcome of carpal tunnel syndrome in patients who are **conservatively treated or untreated**

<b>Prognostic factor</b>	<b>Direction of association and significance</b>	<b>Risk of bias (number of studies)</b>	<b>Number and % of studies demonstrating predictive association with a negative outcome (statistically significant)</b>	<b>Level of evidence</b>
<b>Demographic characteristics</b>				
<b>Female gender</b>	+* <sup>34</sup> + <sup>19</sup> 0 <sup>28, 30, 29</sup> 0 <sup>27</sup>	Moderate (5)   High (1)	2/6: 33%  (1/6: 17 %)	Inconclusive
<b>Increasing age (group not otherwise specified or &gt;50 years)</b>	+* <sup>21, 29</sup> 0 <sup>30, 28</sup> -* <sup>34, 26, 19</sup> +* <sup>27</sup> -* <sup>33</sup> _32	Moderate (7)   High (3)	3/10: 30 %  (3/10: 30 %)	Inconclusive


<b>Obesity</b>	+ <sup>19</sup> -* <sup>26</sup>	Moderate (2)	1/2: 50% (0/2: 0%)	Inconclusive
<b>Litigation</b>	+* <sup>29</sup> 0 <sup>30, 28</sup>	Moderate (3)	1/3: 33% (1/3: 33%)	Inconclusive
<b>Deprivation quintile</b>	- <sup>34</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Vibration tool use</b>	- <sup>34</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Occupation status</b>	+* <sup>29</sup>	Moderate (1)	(1/1: 100)%	Inconclusive
<b>Smoking</b>	+ <sup>34</sup>	Moderate (1)	1/1: 100% (0/1: 0%)	Inconclusive
<b>Comorbidity</b>				
<b>Diabetes</b>	+* <sup>26</sup>	Moderate (1)	(1/1: 100%)	Inconclusive
<b>Diabetes or hypothyroid</b>	+ <sup>19</sup>	Moderate (1)	1/1: 100% (0/1: 0%)	Inconclusive
<b>Pregnancy or injury associated CTS</b>	- <sup>19</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Arthritis</b>	+ <sup>19</sup>	Moderate (1)	1/1: 100% (0/1: 0%)	Inconclusive
<b>Previous fracture or sprain</b>	0 <sup>27</sup>	High (1)	0/1: 0 %	Inconclusive
<b>Stenosing</b>	+* <sup>27</sup>	High (1)	(1/1: 100%)	Inconclusive

<b>flexor tenosynovitis</b>				
<b>Mental health status</b>	+* <sup>29</sup>	Moderate (1)	(1/1: 100%)	Inconclusive
<b>Disease characteristics</b>				
<b>Tinnel's sign positive</b>	+ <sup>34</sup>	Moderate (1)	1/1: 100% (0/1: 0%)	Inconclusive
<b>Phalen's sign positive</b>	+* <sup>21</sup>	Moderate (2)	3/3: 100 %	Inconclusive
	+ <sup>34</sup>		(2/3: 67%)	
	+* <sup>27</sup>	High (1)		
<b>Thenar wasting</b>	+* <sup>28</sup>	Moderate (2)	3/3: 100 %	Inconclusive
	+ <sup>34</sup>		(2/3: 67%)	
	+* <sup>27</sup>	High (1)		
<b>Paraesthesia</b>	+* <sup>27</sup>	High (1)	(1/1: 100%)	Inconclusive
<b>Abnormal two-point discrimination</b>	0 <sup>30</sup>	Moderate (1)	1/2: 50%	Inconclusive
	+* <sup>27</sup>	High (1)	(1/2: 50%)	
<b>Semmes Weinstein monofilament testing</b>	0 <sup>30</sup>	Moderate	0/1: 0 %	Inconclusive
<b>Electrophysiological severity</b>	+ <sup>34</sup> 0 <sup>26</sup> -* <sup>21</sup>	Moderate (3)	2/5: 40% (0/5: 0%)	Inconclusive

	+ <sup>31</sup>	High (2)		
	- <sup>32</sup>			
<b>Symptom severity</b>	-* <sup>26</sup>	Moderate (2)	1/3: 33%	Inconclusive
	-* <sup>21</sup>		(1/3: 33%)	
	+* <sup>33</sup>	High (1)		
<b>Functional severity</b>	+* <sup>29</sup>	Moderate (3)	1/4: 25%	Inconclusive
	-* <sup>26</sup> , <sup>21</sup>		(1/4: 25%)	
	0 <sup>33</sup>	High (1)		
<b>CTS category of severity<sup>19</sup></b>	+* <sup>19</sup>	Moderate (1)	(1/1: 100%)	
<b>Sensory SF-MPQ</b>	+ <sup>34</sup>	Moderate (1)	1/1: 100%	Inconclusive
			(0/1: 0%)	
<b>Affective SF-MPQ</b>	+ <sup>34</sup>	Moderate 1	1/1: 100%	Inconclusive
			(0/1: 0%)	
<b>SF-36</b>	0 <sup>33</sup>	High (1)	0/1: 0 %	Inconclusive
<b>DASH</b>	0 <sup>33</sup>	High (1)	0/1: 0 %	
<b>Hi-Ob</b>	-* <sup>21</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Visual analog scale</b>	+ <sup>34</sup>	Moderate (1)	1/1: 100%	Inconclusive
			(0/1: 0%)	
<b>Laterality: left only</b>	- <sup>19</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Laterality: right only</b>	-* <sup>19</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Laterality: left &gt;</b>	- <sup>19</sup>	Moderate (1)	0/1: 0 %	Inconclusive

<b>right</b>				
<b>Laterality: right &gt; left</b>	- <sup>19</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Bilateral</b>	+ <sup>*21</sup>	Moderate (2)	2/3: 67% (1/3: 33%)	Inconclusive
	+ <sup>34</sup> 0 <sup>27</sup>	High (1)		
<b>Grip strength</b>	0 <sup>30</sup> m - <sup>34</sup> m	Moderate (2)	0/2: 0%	Inconclusive
<b>Hand stress</b>	- <sup>*21</sup>	Moderate (1)	0/1: 0 %	Inconclusive
<b>Increasing symptom duration</b>	+ <sup>* 28, 21</sup>	Moderate (3)	5/5: 100% (3/5: 60%)	Inconclusive
	+ <sup>26</sup>			
	+ <sup>*27</sup>	High (2)		
	+ <sup>32</sup>			
<p>0 = not significant and direction not provided</p> <p>+ = predictive of a negative outcome</p> <p>- = not predictive of a negative outcome</p> <p>* = statistically significant</p> <p>SF-MPQ – Short-Form McGill pain questionnaire</p> <p>SF-36 – Short-Form 36</p> <p>DASH – Disabilities of the arm, shoulder and hand questionnaire</p> <p>Hi-Ob – Historical objective scale</p>				

Figure 1 Study Selection



**Supplementary Table: Medline Search Strategy**

1. median neuropathy/ or exp carpal tunnel syndrome/
2. "carpal tunnel syndrome".mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
3. Nerve Compression Syndromes/
4. entrapment neuropath\*.ti,ab.
5. exp Median Nerve/
6. nerve entrapment\*.ti,ab.
7. Hand/ and Pain/
8. Pain/ and Wrist/
9. (carpal\$ adj3 tunnel\$).mp.
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp Prognosis/
12. exp Disease Progression/
13. prognos\*.mp.
14. predict\*.mp.
15. factor\*.mp.
16. risk\*.mp.
17. model\*.mp.
18. evolution.mp.
19. history.mp.
20. indicator\*.mp.
21. course.mp.
22. rule\*.mp.

23. transition\*.mp.
24. determinant\*.mp.
25. pattern\*.mp.
26. subgroup\*.mp.
27. sub-group\*.mp.
28. screen\*.mp.
29. long-term.mp.
30. progress\*.mp.
31. modif\*.mp.
32. mediat\*.mp.
33. or/11-32
34. exp Epidemiologic Studies/
35. cohort\*.mp.
36. follow-up.mp.
37. follow-up.mp.
38. ("case control" or "case controlled").mp.
39. retrospective\*.mp.
40. prospective\*.mp.
41. ((patient\* or medical) adj3 (record\* or review\* or histor\*)).mp.
42. longitudinal\*.mp.
43. inception.mp.
44. observation\*.mp.
45. time series.mp.
46. outcome\*.mp.
47. or/34-46



48. 33 and 47

59. 10 and 48

ACCEPTED MANUSCRIPT